AWH: Gets SVP Commercial Ops fm WGS

Ms. Snider has spent her 20+ year career in women’s healthcare and diagnostics. She joins Aspira from Sema4 Genomics where she served as Vice President of Market Enablement/Sales Strategy during the company’s extraordinary growth. In this role, she was responsible for women’s health commercial strategy and oversaw its financial and operational performance. Prior to Sema4, Ms. Snider was Vice President of Sales for Sonic Reference Laboratory, Inc., where she led commercial development through the successful launch and growth of esoteric testing. Ms. Snider returns to the company having been part of the commercial leadership team during the development and launch of Ova1 after joining Aspira from Myriad.

“Michelle has an impressive track record of success in women’s health diagnostics. Her knowledge and expertise, as well as her vast industry relationships, will be extremely valuable as we enter the next phase of our commercial refresh,” said Nicole Sandford, Chief Executive Officer of Aspira. “Michelle has experience successfully launching new products as well as accelerating commercial growth for more mature offerings. Our team will thrive under her leadership, and I am happy to welcome her back.”

Ms. Snider added, “I am thrilled to rejoin the Aspira team. I am more convinced than ever that Aspira’s diagnostic tools have the potential to dramatically change the standard of care for both ovarian cancer and endometriosis. I look forward to bringing my experience to the table to accelerate the company’s growth through both its sales force and strategic commercial partnerships.”

About Aspira Women’s Health Inc.
Aspira Women’s Health Inc. is transforming women’s gynecological health with the discovery, development, and commercialization of innovative testing options for women of all races and ethnicities, starting with ovarian cancer.

Our ovarian cancer risk assessment portfolio is marketed to healthcare providers as OvaSuite SM . OvaWatch SM is a non-invasive, blood-based test intended for use in the initial clinical assessment of ovarian cancer risk in women with benign or indeterminate adnexal masses for which surgical intervention may be either premature or unnecessary. With a negative predictive value (NPV) of 99%, OvaWatch allows physicians to confidently rule out ovarian cancer malignancy and choose the appropriate clinical management for the right patient at the right time. Ova1Plus® combines our FDA-cleared products, Ova1® and Overa®, to detect risk of ovarian malignancy in women with adnexal masses planned for surgery.

EndoCheck SM , Aspira’s first-of-its-kind non-invasive diagnostic test for endometriosis, is currently in development. Visit our website for more information at www.aspirawh.com .